Black Diamond Therapeutics Inc’s recently made public that its 10% Owner BIOTECH GROWTH N V unloaded Company’s shares for reported $12.0 million on Mar 19 ’25. In the deal valued at $2.07 per share,5,784,292 shares were sold. As a result of this transaction, BIOTECH GROWTH N V now holds 2,733,547 shares worth roughly $8.04 million.
Guggenheim initiated its Black Diamond Therapeutics Inc [BDTX] rating to a Buy in a research note published on September 04, 2025; the price target was $8. Raymond James began covering BDTX with “an Outperform” recommendation on July 31, 2024. Piper Sandler started covering the stock on July 14, 2023. It rated BDTX as “an Overweight”.
Price Performance Review of BDTX
On Friday, Black Diamond Therapeutics Inc [NASDAQ:BDTX] saw its stock jump 2.44% to $2.94. Over the last five days, the stock has gained 3.16%. Black Diamond Therapeutics Inc shares have fallen nearly -49.05% since the year began. Nevertheless, the stocks have risen 37.38% over the past one year. While a 52-week high of $6.33 was reached on 07/21/25, a 52-week low of $1.20 was recorded on 04/09/25.
Levels Of Support And Resistance For BDTX Stock
The 24-hour chart illustrates a support level at 2.87, which if violated will result in even more drops to 2.80. On the upside, there is a resistance level at 3.01. A further resistance level may holdings at 3.08.
How much short interest is there in Black Diamond Therapeutics Inc?
A steep rise in short interest was recorded in Black Diamond Therapeutics Inc stocks on 2025-08-15, growing by 0.84 million shares to a total of 6.9 million shares. Yahoo Finance data shows the prior-month short interest on 2025-07-15 was 6.06 million shares. There was a rise of 12.11%, which implies that there is a positive sentiment for the stock.
